Targeted therapies in the treatment of non-small cell lung cancer;Les thérapies ciblées dans le traitement du cancer bronchique non à petites cellules

Bulletin du Cancer

Volumn 95, Issue 3, 2008, Pages 358-364

  De Grève, Jacques ^a   Decoster, Lore ^a   Van Meerbeek, Jan ^a   Vermeij, Joanna ^a   Teugels, Erik ^a   Schallier, Denis ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Angiogenesis; Bevacizumaberlotinib; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; VASCULOTROPIN;

ANGIOGENESIS; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSPNEA; FATIGUE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 42149089912     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0591     Document Type: Review

References (36)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 ; 346 : 92-8.
2. Hubert P. {Growth factors of the EGF family and their receptors}. Bull Cancer 2007 ; 94 : F137-45.
3. Grenier J, Soria JC. {Inhibitors of the EGFR pathway in non small cell lung cancer : what's new in 2007?}. Bull Cancer 2007 ; 94 : 53-61.
4. Simon JM. {Hypoxia and angiogenesis}. Bull Cancer 2007 ; 94 : S160-5.
5. Ruegg C, Mutter N. Anti-angiogenic therapies in cancer : achievements and open questions. Bull Cancer 2007 ; 94 : 753-62.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100 : 57-70.
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003 ; 9 : 669-76.
8. Perol M, Arpin D. {Angiogenesis and lung cancer}. Bull Cancer 94 Spec No : S220-31 2007.
9. Planchard D, Besse B. {Angiogenesis targeting in lung cancers}. Bull Cancer 2007 ; 94 : F217-22.
10. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996 ; 73 : 931-4.
11. Seto T, Higashiyama M, Funai H, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 2006 ; 53 : 91-6.
12. Rad FH, Le Buanec H, Paturance S, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 2007 ; 104 : 2837-42.
13. Warren RS, Yuan H, Matli MR, et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995 ; 95 : 1789-97.
14. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993 ; 362 : 841-4.
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 ; 350 : 2335-42.
16. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 ; 22 : 2184-91.
17. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 ; 355 : 2542-50.
18. Manegold C, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, et al. The BO17704 study group. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer. J Clin Oncol 2007 ; 18S :LBA7514.
19. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004 ; 10 : 145-7.
20. Manegold C, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, et al. The BO17704 study group : Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer. J Clin Oncol 2007 ; 18S :LBA7514.
21. Italiano A, Besse B, Planchard D, et al. {Targeting epidermal growth factor receptor in non-small cell lung cancer : current advances and perspectives}. Bull Cancer 2007 ; 94 : F177-88.
22. Herbst RS, Prager D, Hermann R, et al. Tribute : a phase III trial of erlotinib hydrochloride (OSI774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005 ; 123 : 5892-9.
23. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 ; 353 : 123-32.
24. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006 ; 24 : 5034-42.
25. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer : molecular and clinical predictors of outcome. N Engl J Med 2005 ; 353 : 133-44.
26. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 ; 350 : 2129-39.
27. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006 ; 12 : 3908-14.
28. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007 ; 25 : 760-6.
29. Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005 ; 11 : 3032-7.
30. Paz-Ares L, García-Velasco A, Massuti B, López-Vivanco G, Provencio M, Montes A, et al., Spanish Lung Cancer Group. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer patients (p) with mutations in the tyrosine kinase domain of the epidermal growth factor receptor. J Clin Oncol 2006 ; 24(Suppl.) : 7020.
31. De Grève J, Schallier D, Van Meerbeek J, Vansteenkiste J. First-line EGFR-1 tyrosine kinase inhibition in patients with NSCLC with a mutant EGFR gene. http://clinicaltrials.gov/ct2/show/NCT00339586.
32. Lilenbaum RAR, Thomas S, Dowlati A, Seigel L, Albert D, Van Duym C, et al. Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer and performance status of 2. J Clin Oncol 2006 ; 24(suppl.) : 7022.
33. Douillard J, Hirsh V, Mok T, Socinski M, Wu Y, Li L, et al. Gefitinib (Iressa) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy : a randomized, open-label Phase III study (Interest). J Thor Oncol 2007 ; 5305-6 : S4.
34. Kelly K, Gaspar LE, Jett JR, Ung Y, Albain KS, Crowley JJ, et al. Updated analysis of SWOG 0023 : a randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J Clin Oncol 2001 ; 25 : 7513.
35. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005 ; 2 : e73.
36. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2001 ; 316 : 1039-43.